FDA Public Hearing: Scientific Data and Info About Cannabis Products

Event Information

Share this event

Date and Time

Location

Location

FDA White Oak Campus

10903 New Hampshire Avenue

Building 31, Room 1503 - Great Room

Silver Spring, MD 20993

View Map

Event description
Scientific Data and Information About Products Containing Cannabis or Cannabis-Derived Compounds; Public Hearing

About this Event

Cannabis is a plant of the Cannabaceae family and contains more than 80 biologically active chemical compounds. The most commonly known compounds are delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). Parts of the Cannabis sativa plant have been controlled under the Federal Controlled Substances Act (CSA) since 1970 under the drug class “Marihuana” (21 U.S.C. 802(16).[1] “Marihuana” is listed in Schedule I of the CSA due to its high potential for abuse, which is attributable in large part to the psychoactive effects of THC, and the absence of a currently accepted medical use for marijuana in the United States. Cannabis and cannabis-derived products have been the subject of increasing interest by consumers, industry, researchers, the public, and regulators. Regulatory oversight of products containing cannabis or cannabis-derived compounds is complex and involves multiple Federal and State agencies.

The goal of the hearing is to obtain additional scientific data and other information related to cannabis and cannabis-derived compounds, both from botanical and synthetic sources, to inform our regulatory oversight of these products. This hearing is particularly important in light of the passage of the Agriculture Improvement Act of 2018, Public Law 115-334 (the 2018 Farm Bill), which, among other things removed the plant Cannabis sativa L. or “hemp” from the Controlled Substances Act. While the Farm Bill is intended to facilitate the production and marketing of hemp, it explicitly preserved FDA's authority to regulate hemp products. FDA does not intend for this hearing to produce any decisions or new positions on specific regulatory questions, but this hearing is expected to be an important step in our continued evaluation of all cannabis and cannabis-derived compounds in FDA-regulated products, including products containing hemp.

As stated in the Federal Register notice, requests to make a presentation/provide oral comments during the hearing must be received by May 10th. Due to space and time limitations, it is possible that not all can be accommodated. Therefore, registering on this site does not guarantee a time slot to make a presentation/provide oral comments. Your confirmation to make a presentation/provide oral comments will be provided by May 21, 2019. Registrants can also view the hearing via webcast. All meeting attendees and other interested parties may submit information to the public docket FDA-2019-N-1482.

For more information about the meeting, as well as how to submit written comments afterwards, see the FDA Event Page. For general questions about the meeting or to request special accommodations due to a disability, contact Beth F. Fritsch, Food and Drug Administration, 10903 New Hampshire Ave. Bldg. 32, Rm. 5308, Silver Spring, MD 20993, phone: 301-796-8451,email: StakeholderEngagement@fda.hhs.gov

Date and Time

Location

FDA White Oak Campus

10903 New Hampshire Avenue

Building 31, Room 1503 - Great Room

Silver Spring, MD 20993

View Map

Save This Event

Event Saved